Heart Failure Clinical Trials in St Louis, Missouri

17 studies are recruiting for heart failure in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Alleviant ALLAY-HFrEF Study

   Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Washington University - St Louis, St Louis, Missouri

   Locations

   68 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT06812533 on ClinicalTrials.gov

2. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, St Louis, Missouri

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

3. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   WashU Medicine, St Louis, Missouri

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

4. A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

   This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find ou…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   St. Louis Heart and Vascular, P.C., St Louis, Missouri

   Locations

   588 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06935370 on ClinicalTrials.gov

5. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

   This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

   Stage

   Phase 2

   Ages

   0 to 17

   Site

   Washington University-Pediatric Cardiology/ St. Louis Children's Hospital ( Site 0006), St Louis, Missouri

   Locations

   109 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05714085 on ClinicalTrials.gov

6. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Washington University Center for Advanced Medicine, St Louis, Missouri

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

7. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

   This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   St. Louis Heart and Vascular, P.C., St Louis, Missouri

   Locations

   652 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06424288 on ClinicalTrials.gov

8. A Study of LY3971297 in Participants With Heart Failure

   The main purpose of this study is to assess how well LY3971297 is tolerated and what side effects may occur in participants with heart failure with preserved ejection fraction (HFpEF) and participants with heart failure with reduced ejection fraction (HFrEF). Blood tests will be performed to invest…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Washington University, St Louis, Missouri

   Locations

   12 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07547540 on ClinicalTrials.gov

9. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

   The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

   Stage

   Not phased

   Ages

   Any age

   Site

   Research site, St Louis, Missouri

   Locations

   333 in total

   Run by

   Medtronic

   See if you can join NCT00271180 on ClinicalTrials.gov

10. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Washington University, St Louis, Missouri

    Locations

    838 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

11. Alleviant ALLAY-HF Study

    Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

    Stage

    Not phased

    Ages

    40 and older

    Site

    Washington University - St Louis, St Louis, Missouri

    Locations

    93 in total

    Run by

    Alleviant Medical, Inc.

    See if you can join NCT05685303 on ClinicalTrials.gov

12. A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

    This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…

    Stage

    Phase 2

    Ages

    40 to 84

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    117 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT06979362 on ClinicalTrials.gov

13. The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)

    The goals of this project are to determine the effectiveness of acute (2 hours after a single dose) and chronic (after 6 weeks of once-a-day dosing) KNO3 treatment (10mmol) vs. placebo on quadriceps muscle power and on aerobic exercise performance (V̇O2peak) in patients with HFrEF (left ventricular…

    Stage

    Phase 2

    Ages

    19 to 79

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05562167 on ClinicalTrials.gov

14. The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

    The objective of this prospective, randomized, double- blinded (patient and assessors), sham-controlled clinical trial is to assess the safety and efficacy of the CMCS in treating heart failure with functional regurgitation (FMR).

    Stage

    Not phased

    Ages

    18 and older

    Site

    St. Louis Heart and Vascular, St Louis, Missouri

    Locations

    92 in total

    Run by

    Cardiac Dimensions, Inc.

    See if you can join NCT03142152 on ClinicalTrials.gov

15. Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because …

    Stage

    Phase 3

    Ages

    18 to 75

    Site

    Washington University, St Louis, Missouri

    Locations

    19 in total

    Run by

    Alessandro Doria

    See if you can join NCT06217302 on ClinicalTrials.gov

16. XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

    The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University - Barnes Jewish Health Hospital, St Louis, Missouri

    Locations

    14 in total

    Run by

    XVIVO Perfusion

    See if you can join NCT06895070 on ClinicalTrials.gov

17. Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

    It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that corre…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    Washington University in Saint Louis, St Louis, Missouri

    Locations

    5 in total

    Run by

    Sardocor Corp.

    See if you can join NCT04703842 on ClinicalTrials.gov